R

Retina Northwest, PC | Portland, OR

Research site
(Unclaimed)
Location
54450 SW Westgate Drive, Suite 217, Portland, Oregon, United States of America

Site insights

Top conditions

Top treatments

Bevacizumab
Ranibizumab
-Ranibizumab
APL-2
ranibizumab
Pegcetacoplan
NSAID
EPA
Triamcinolone Acetonide
DHA

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 24 total trials

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) i...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Trial sponsors

Jaeb Center for Health Research logo
A
AbbVie logo
Bayer logo
I
National Institutes of Health (NIH) logo
N
The EMMES Corporation logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems